Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
NeuroTransmitter
Erschienen in: NeuroTransmitter 12/2012

07.12.2012 | Fortbildung

Für jeden Patienten den optimalen Wirkstoff finden

Antidepressive Pharmakotherapie

verfasst von: Dr. med. Martin Lieb, Prof. Dr. med. Rainer Rupprecht, Prof. Dr. med. Thomas C. Baghai

Erschienen in: NeuroTransmitter | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

In ihrer Wirksamkeit unterscheiden sich die einzelnen Klassen von Antidepressiva nur wenig. Es gibt jedoch Wirkunterschiede, die für den einzelnen Patienten und für die Behandlung diagnostischer Subgruppen depressiver Störungen durchaus von Bedeutung sind. Auch das Alter und somatische Begleiterkrankungen des Patienten spielen für die Auswahl eines Antidepressivums eine nicht unbeträchtliche Rolle. Eine individuelle Differenzialtherapie ist daher Voraussetzung für eine wirksame und verträgliche Behandlung, nicht zuletzt im Interesse der Therapietreue.

Literatur
  1. Adli M., Baethge C., Heinz A., Langlitz N., Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387–400.PubMedView Article
  2. AHCPR (Agency for Health Care Policy and Research). Evidence report on Treatment of depression: Newer Pharmacotherapies. Washington DC: AHCPR, 1999.
  3. Amsterdam J.D., Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression - A retrospective study. J Affect Disord 2005; 89(1–3): 183–188.PubMedView Article
  4. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58(1): 19–36.PubMedView Article
  5. Anderson I.M. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl 1: 11–17.PubMedView Article
  6. Baghai T.C., Blier P., Baldwin D.S, Bauer M., Goodwin G.M., Fountoulakis K.N. et al. Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. Eur Arch Psychiatry Clin Neurosci 2012; 262(1): 13–22.PubMedView Article
  7. Baghai T.C., Blier P., Baldwin D.S., Bauer M., Goodwin G.M., Fountoulakis K.N. et al. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2011; 261 Suppl 3: 207–245.PubMedView Article
  8. Baghai T.C., Volz H.P., Moller H.J. Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006; 7(4): 198–222.PubMedView Article
  9. Baldwin D.S. Escitalopram: efficacy and tolerability in the treatment of depression. Hosp Med 2002; 63(11): 668–671.PubMed
  10. Barkin R.L., Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 2005; 12(5): 431–438.PubMedView Article
  11. Bauer M., Bschor T., Pfennig A., Whybrow P.C., Angst J., Versiani M. et al. Biologische Behandlung unipolarer depressiver Störungen in der allgemeinärztlichen Versorgung. Psychopharmakotherapie 2008; 15(6): 239–264.
  12. Bauer M., Bschor T., Pfennig A., Whybrow P.C., Angst J., Versiani M. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8(2): 67–104.PubMedView Article
  13. Bauer M., Whybrow P.C., Angst J., Versiani M., Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002; 3(2): 69–86.PubMedView Article
  14. Benkert O., Muller M., Szegedi A. An overview of the clinical efficacy of mirtazapine. Hum Psychopharmacol 2002; 17 Suppl 1: S23–S26.PubMedView Article
  15. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S. et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47(4): 351–354.PubMedView Article
  16. Berzewski H., van M.M., Gagiano C.A. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997; 7 Suppl 1: S37–S47.PubMedView Article
  17. Bezchlibnyk-Butler K., Aleksic I., Kennedy S.H. Citalopram—a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000; 25(3): 241–254.PubMed
  18. Bielski R.J., Ventura D., Chang C.C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65(9): 1190–1196.PubMedView Article
  19. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003; 9(1): 97–140.PubMedView Article
  20. Boulenger J.P., Huusom A.K., Florea I., Baekdal T., Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006; 22(7): 1331–1341.PubMedView Article
  21. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005; 352(11): 1112–1120.PubMedView Article
  22. Burrows G.D., Maguire K.P., Norman T.R. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998; 59 Suppl 14: 4–7.PubMed
  23. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L. et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25(6): 871–880.PubMedView Article
  24. Calil H.M. Fluoxetine: a suitable long-term treatment. J Clin Psychiatry 2001; 62 Suppl 22: 24–29.PubMed
  25. Charney D.S., Grothe D.R., Smith S.L., Brady K.T., Kaltsounis-Puckett J., Wright C.W. et al. Overview of psychiatric disorders and the role of newer antidepressants. J Clin Psychiatry 2002; 63: 3–9.PubMed
  26. Cheeta S., Schifano F., Oyefeso A., Webb L., Ghodse A.H. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 2004; 184: 41–47.PubMedView Article
  27. Cipriani A., Barbui C., Brambilla P., Furukawa T.A., Hotopf M., Geddes J.R. Are All Antidepressants Really the Same? The Case of Fluoxetine: A Systematic Review. J Clin Psychiatry 2006; 67(6): 850–864.PubMedView Article
  28. Clayton A.H., Zajecka J., Ferguson J.M., Filipiak-Reisner J.K., Brown M.T., Schwartz G.E. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 2003; 18(3): 151–156.PubMed
  29. Clerc G.E., Ruimy P., Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994; 9(3): 139–143.PubMedView Article
  30. Coleman C.C., King B.R., Bolden-Watson C., Book M.J., Segraves R.T., Richard N. et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001; 23(7): 1040–1058.PubMedView Article
  31. Croft H., Settle E. Jr., Houser T., Batey S.R., Donahue R.M., Ascher J.A. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21(4): 643–658.PubMedView Article
  32. Dardennes R.M., Even C., Ballon N., Bange F. Serotonin syndrome caused by a clomipramine-moclobemide interaction. J Clin Psychiatry 1998; 59(7): 382–383.PubMedView Article
  33. Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., Demitrack M.A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63(4): 308–315.PubMedView Article
  34. Detke M.J., Wiltse C.G., Mallinckrodt C.H., McNamara R.K., Demitrack M.A., Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14(6): 457–470.PubMedView Article
  35. Edwards J.G., Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57(4): 507–533.PubMedView Article
  36. Eker S.S., Akkaya C., Akgoz S., Sarandol A., Kirli S. [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. Turk Psikiyatri Derg 2005; 16(3): 153–163.PubMed
  37. Fava M., Rush A.J., Thase M.E., Clayton A., Stahl S.M., Pradko J.F. et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7(3): 106–113.PubMedView Article
  38. Feighner J., Hendrickson G., Miller L., Stern W. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986; 6(1): 27–32.PubMedView Article
  39. Ferguson J.M. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry 2001; 3(1): 22–27.PubMedView Article
  40. Goldstein D.J., Lu Y., Detke M.J., Wiltse C., Mallinckrodt C., Demitrack M.A. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24(4): 389–399.PubMedView Article
  41. Green B. Focus on paroxetine. Curr Med Res Opin 2003; 19(1): 13–21.PubMedView Article
  42. Grunze H., Kasper S., Goodwin G., Bowden C., Baldwin D., Licht R. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002; 3(3): 115-124.PubMedView Article
  43. Guelfi J.D., Ansseau M., Timmerman L., Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21(4): 425–431.PubMedView Article
  44. Guelfi J.D., Bouhassira M., Bonett-Perrin E., Lancrenon S. [The study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients followed in general practice]. Encephale 1999; 25(3): 265–270.PubMed
  45. Haddad P. Do antidepressants have any potential to cause addiction? J Psychopharmacol 1999; 13(3): 300–307.PubMedView Article
  46. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4): 278–296.PubMedView Article
  47. Henkel V., Mergl R., Allgaier A.K., Kohnen R., Möller H.J., Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 2006; 141(1): 89–101.PubMedView Article
  48. Himmelhoch J.M., Thase M.E., Mallinger A.G., Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148(7): 910–916.PubMed
  49. Hirschfeld R.M., Vornik L.A. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 2004; 65 Suppl 4: 46–52.PubMed
  50. Holzer M., Langer A., Muller N. [Consequences of public discussion on the ineffectiveness of antidepressives: attempted suicide after stopping medication]. Nervenarzt 2008; 79(9): 1074–1075.PubMedView Article
  51. Horne R.L., Ferguson J.M., Pope H.G., Jr., Hudson J.I., Lineberry C.G., Ascher J. et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49(7): 262–266.PubMed
  52. Jonsson A., Holmgren P., Ahlner J. Fatal intoxications in a Swedish forensic autopsy material during 1992-2002. Forensic Sci Int 2004; 143(1): 53–59.PubMedView Article
  53. Kasper S., Möller H.J. Antidepressive Psychopharmakatherapie: selektive Serotonin-Wiederaufnahmehemmer (SSRI) als neues Wirkprinzip. Deutsches Ärzteblatt 1995; 92: A428–434.
  54. Kasper S., Olie J.P. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 2002; 17 Suppl 3: 331–340.PubMedView Article
  55. Kasper S., Spadone C., Verpillat P., Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006; 21(2): 105–110.PubMedView Article
  56. Kennedy S.H., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16(2): 93–100.PubMedView Article
  57. Kennedy S.H., Rizvi S., Fulton K., Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28(3): 329–333.PubMedView Article
  58. Khouzam H.R., Emes R., Gill T., Raroque R. The antidepressant sertraline: a review of its uses in a range of psychiatric and medical conditions. Compr Ther 2003; 29(1): 47–53.PubMedView Article
  59. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5(2):–e45.PubMedView Article
  60. Koski A., Vuori E., Ojanpera I. Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. Int J Legal Med 2005; 119(6): 344–348.PubMedView Article
  61. Kupfer D.J. Long-term treatment of depression. J Clin Psychiatry 1991; 52 Suppl: 28–34.PubMed
  62. Kupfer D.J. The pharmacological management of depression. Dialogues Clin Neurosci 2005; 7(3): 191–205.PubMed
  63. Launay D., Queyrel V., Hatron P.Y., Michon-Pasturel U., Caron J., Hachulla E. et al. [Agranulocytosis connected with the taking of mianserin: a complication to be feared in the aged]. Rev Med Interne 2000; 21(7): 642–643.PubMedView Article
  64. Laux G. The Antidepressant Agomelatine in Daily Practice: Results of the Non-Interventional Study VIVALDI. Pharmacopsychiatry 2012.
  65. Leverich G.S., Altshuler L.L., Frye M.A., Suppes T., McElroy S.L., Keck P.E., Jr. et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163(2): 232–239.PubMedView Article
  66. Loo H., Dalery J., Macher J.P., Payen A. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders]. Encephale 2002; 28(4): 356–362.PubMed
  67. Loo H., Dalery J., Macher J.P., Payen A. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders]. Encephale 2003; 29(2): 165–171.PubMed
  68. Loo H., Deniker P. Position of tianeptine among antidepressive chemotherapies. Clin Neuropharmacol 1988; 11 Suppl 2: S97–102.PubMed
  69. Loo H., Hale A., D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17(5): 239–247.PubMedView Article
  70. Lotufo-Neto F., Trivedi M., Thase M.E. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20(3): 226–247.PubMedView Article
  71. Mace S., Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 2000; 1(5): 917–933.PubMedView Article
  72. Massana J., Moller H.J., Burrows G.D., Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999; 14(2): 73–80.PubMedView Article
  73. Mattia C., Paoletti F., Coluzzi F., Boanelli A. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol 2002; 68(3): 105–114.PubMed
  74. McEwen B.S., Olie J.P. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry 2005; 10(6): 525–537.PubMedView Article
  75. McGrath P.J., Stewart J.W., Fava M., Trivedi M.H., Wisniewski S.R., Nierenberg A.A. et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163(9): 1531–1541.PubMedView Article
  76. Möller H.J., Kasper S., Muller H., Kissling W., Fuger J., Ruhrmann S. A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients. Pharmacopsychiatry 1995; 28(6): 249–252.PubMedView Article
  77. Möller H.J. Are all antidepressants the same? J Clin Psychiatry 2000; 61 Suppl 6: 24–28.PubMed
  78. Montgomery S.A., Andersen H.F. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21(5): 297–309.PubMedView Article
  79. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389.PubMedView Article
  80. Montgomery S.A., Baldwin D.S., Blier P., Fineberg N.A., Kasper S., Lader M. et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007; 22(6): 323–329.PubMedView Article
  81. Montgomery S.A., Kennedy S.H., Burrows G.D., Lejoyeux M., Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19(5): 271–280.PubMedView Article
  82. Montgomery S.A., Möller H.J. Is the significant superiority of escitalopram compared to other antidepressants clinically relevant? In preparation 2008.
  83. Montgomery S.A. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005; 59(12): 1435–1440.PubMedView Article
  84. Montgomery S.A. Chairman’s overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998; 59 Suppl 14: 26–29.PubMed
  85. Montgomery S.A. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl 4: 37–45.PubMedView Article
  86. Moore N., Verdoux H., Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20(3): 131–137.PubMedView Article
  87. Nierenberg A.A., Ostacher M.J., Huffman J.C., Ametrano R.M., Fava M., Perlis R.H. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med 2008; 50(4): 428–436.PubMedView Article
  88. Olver J.S., Burrows G.D., Norman T.R. The treatment of depression with different formulations of venlafaxine: a comparative analysis. Hum Psychopharmacol 2004; 19(1): 9–16.PubMedView Article
  89. Olver J.S., Burrows G.D., Norman T.R. Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 2001; 15(12): 941–954.PubMedView Article
  90. Ozcanli T., Unsalver B., Ozdemir S., Ozmen M. Sertraline- and mirtazapine-induced severe neutropenia. Am J Psychiatry 2005; 162(7): 1386.PubMedView Article
  91. Papakostas G.I., Homberger C.H., Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008.
  92. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002; 106(3): 168–170.PubMedView Article
  93. Pineyro G., Deveault L., Blier P., Dennis T., de M.C. Effect of acute and prolonged tianeptine administration on the 5-HT transporter: electrophysiological, biochemical and radioligand binding studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1995; 351(2): 111–118.PubMed
  94. Post R.M., Altshuler L.L., Leverich G.S., Frye M.A., Nolen W.A., Kupka R.W. et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006; 189: 124–131.PubMedView Article
  95. Ramana R., Paykel E.S., Cooper Z., Hayhurst H., Saxty M., Surtees P.G. Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 1995; 25(6): 1161–1170.PubMedView Article
  96. Rampello L., Chiechio S., Nicoletti G., Alvano A., Vecchio I., Raffaele R. et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl) 2004; 173(1–2): 73–78.View Article
  97. Remick R.A., Campos P.E., Misri S., Miles J.E., Van Wyck F.J. A comparison of the safety and efficacy of bupropion HCL and amitriptyline hcl in depressed outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6(4–6): 523–527.PubMedView Article
  98. Robinson D.S., Gilmor M.L., Yang Y., Moonsammy G., Azzaro A.J., Oren D.A. et al. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacol Bull 2007; 40(3): 15–28.PubMed
  99. Rottach K.G., Schaner B.M., Kirch M.H., Zivotofsky A.Z., Teufel L.M., Gallwitz T. et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008; 43(1): 70–75.PubMedView Article
  100. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905–1917.PubMedView Article
  101. Saarto T., Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005;(3): CD005454.
  102. Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365(9458): 482–487.PubMed
  103. Sartorius N., Baghai T.C., Baldwin D.S., Barrett B., Brand U., Fleischhacker W. et al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol 2007; 10 Suppl 1: S1–207.PubMed
  104. Sartorius N. Description and classification of depressive disorders. Contributions for the definition of the therapy-resistance and of therapy resistant depressions. Pharmakopsychiatr Neuropsychopharmakol 1974; 7(2): 76–79.PubMed
  105. Schatzberg A.F., Kremer C., Rodrigues H.E., Murphy G.M., Jr. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10(5): 541–550.PubMed
  106. Shepherd G., Velez L.I., Keyes D.C. Intentional bupropion overdoses. J Emerg Med 2004; 27(2): 147–151.PubMedView Article
  107. Sir A., D’souza R.F., Uguz S., George T., Vahip S., Hopwood M.et al. Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms. J Clin Psychiatry 2005; 66(10): 1312–1320.PubMedView Article
  108. Smith D., Dempster C., Glanville J., Freemantle N., Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180: 396–404.PubMedView Article
  109. Stahl S.M., Grady M.M., Moret C., Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10(9): 732–747.PubMed
  110. Sultan A., Gaskell H., Derry S., Moore R.A. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 2008; 8: 29.PubMedView Article
  111. Thase M.E., Baker R.A., Simmons J.H., Van Willigenburg A.P., Schutte A.J. Effects of mirtazapine versus SSRIs on core symptoms of depression. J Affect.Disord. 2006; 91[S1]: S83.
  112. Thase M.E., Shelton R.C., Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006; 26(3): 250–258.PubMedView Article
  113. Thase M.E., Trivedi M.H., Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12(3): 185–219.PubMedView Article
  114. Thase M.E. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60 Suppl 17: 28–31.PubMed
  115. Tran P.V., Bymaster F.P., McNamara R.K., Potter W.Z. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23(1): 78–86.PubMedView Article
  116. Van Ameringen A.P., Ferrey G., Tournoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J Affect Disord 2002; 72(1): 21–31.View Article
  117. Venlafaxine vs. SSRIs: Comparison of somatic symptom reduction. Conference of the Americal Psychiatric Association (APA); 2004.
  118. Vis P.M., van B.M., Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005; 39(11): 1798–1807.PubMedView Article
  119. Ware M.R. Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry 1997; 58 Suppl 5: 15–23.PubMed
  120. Weihs K.L., Settle E.C., Jr., Batey S.R., Houser T.L., Donahue R.M., Ascher J.A. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61(3): 196–202.PubMedView Article
  121. Wheatley D.P., van M.M., Timmerman L., Kremer C.M. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 1998; 59(6): 306–312.PubMedView Article
  122. Workman E.A., Short D.D. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry 1993; 54(1): 5–12.PubMed
  123. Wu J.C., Bunney W.E. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 1990; 147(1): 14–21.PubMed
  124. Zimmerman M., McGlinchey J.B., Posternak M.A., Friedman M., Attiullah N., Boerescu D. How Should Remission From Depression Be Defined? The Depressed Patient’s Perspective. Am J Psychiatry 2006; 163(1): 148–150.PubMedView Article
Metadaten
Titel
Für jeden Patienten den optimalen Wirkstoff finden
Antidepressive Pharmakotherapie
verfasst von
Dr. med. Martin Lieb
Prof. Dr. med. Rainer Rupprecht
Prof. Dr. med. Thomas C. Baghai
Publikationsdatum
07.12.2012
Verlag
Urban and Vogel
Erschienen in
NeuroTransmitter / Ausgabe 12/2012
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI
https://doi.org/10.1007/s15016-012-0565-x

Weitere Artikel der Ausgabe 12/2012

NeuroTransmitter 12/2012 Zur Ausgabe

Rund um den Beruf

Ein Sammelband an der Anmeldung reicht völlig aus

Editorial

Aus für den Strafzoll für Kranke

Die Verbände informieren

Auszeichnung für sportpsychiatrischen Ansatz

Fortbildung

Ausgezeichnete Forschung und Innovationen

Journal

Psychiater erzählen

Journal

Leitlinien für Diagnostik und Therapie in der Neurologie

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

19.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Hustenstiller lindert Agitation bei Alzheimer
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise